PREVENTION OR TREATMENT OF OVERWEIGHT AND OBESITY IN PATIENTS WITH TYPE 2 DIABETES

摘要

1. The use of a composition with an energy value of from 0.9 to 1.5 kcal / ml, containing isomaltulose and a protein source, where the specified protein source is from 12 to 25 en.% Of the total composition, and containing at least 10 wt.% aspartate equivalents of the total protein content to produce a product for: a. dietary management of cholesterol or triglycerides in patients with type 2 diabetes b. prevention and / or treatment of obesity in patients with type 2 diabetes; and / or c. prevention and / or treatment of cardiovascular disease in patients with type 2 diabetes. 2. The use according to claim 1, where the product contains 10 to 14 wt.% Digestible carbohydrates, and where the specified isomaltulose is from 20 to 80 wt.% Of the total weight of digestible carbohydrates. 3. The use according to claim 1 or 2, wherein the composition further comprises one or more non-digestible carbohydrates selected from the group consisting of galcatooligosaccharides, fructooligosaccharides, inulin, resistant dextrin, resistant starch, cellulose, pectin or pectin degradation products. 4. The use according to claim 1 or 2, wherein said patient to whom the composition is administered has a BMI of at least 25 kg / m. The use according to claim 1 or 2, wherein said protein source in the composition comprises whey protein and / or soy protein, and / or their hydrolysates, concentrates and / or isolates. The use according to claim 5, comprising whey and soy protein, and / or hydrolysates, concentrates and / or isolates in a mass ratio ranging from 2: 1 to 1: 2.7. The use of claim 1 or 2, wherein said composition has a mass ratio of aspartate equivalents to glutamate equivalents of at least 0.45: 1.8. The use according to claim 1 or 2, where the specified product